ROBO4 and ovarian cancer: Further analysis led to identification of a 35 gene “prime/boost” signature unique to only MIS416 Vax + MRB-OVA therapy (Fig. 5a) that, when mapped to publicly available ovarian cancer patient data from TCGA (n = 307 patients), separated patients into 3 distinct clusters (Fig. 5b), one of which correlated with improved clinical outcome (Fig. 5c).